spacer
home > ebr > spring 2017 > seize the market
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

Industry Events

Outsourcing in Clinical Trials Medical Devices 2017

27-28 June 2017, Santa Clara, CA

OCT Medical Devices moved to Irvine, California for the first year in 2016, and we are pleased to say it proved a resounding success. As the only event to cater for the Southern California Medical device hub in Irvine, it brought together a variety of medical device companies of all sizes, including Medtronic, Edwards Lifesciences, Onciomed, Inc and St Jude Medical.
More info >>

 
News and Press Releases

Tagrisso Receives Full Approval in the EU

Full approval follows Tagrisso’s expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer Tagrisso is a potential new standard of care in 2nd line and subsequent therapy in this hard-to-treat form of lung cancer Approval is based on Phase III AURA3 data which demonstrate significant clinical superiority of Tagrisso over chemotherapy in EGFR T790M mutation-positive NSCLC patients, including those with CNS metastases
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement